When investment firm RTW formed Yarrow Biotechnology, they knew they needed to build a top scientific leadership team to advance their antisense oligonucleotide-based therapeutics program. While the science is sound, they also knew attracting candidates to join a company this early stage that didn’t yet have a website would be no easy task.
Based on the successful relationship they had built with Stevenson; they knew just where to turn. With our vast experience building executive teams for incubators and start-ups, Stevenson was able to uniquely tell Yarrow’s story and the opportunity in the very small and highly competitive ASO space. Stevenson’s deep network in the biotech community allows us to quickly access leaders who trust us and will take time to listen to a unique opportunity.
Partnering closely with RTW’s company creation team throughout the search, we were able to deliver a highly qualified slate of executive talent, ultimately appointing their Chief Scientific Officer, Chief Technology Officer, and Vice President of Non-clinical Development. The results exceeded RTW’s expectations of the talent they could attract in this market and has led to an expanding partnership with RTW’s company creation team.
